Preclinical
IND-enabling
Phase 1
Phase 2 (Pivotal)
Submission
Next Milestone
GO-4
Stage IV BRCA-mutated pancreatic cancer
End of phase 1 FDA meeting in Q3 2025; Preliminary Phase 1 data release in Q4 2025; Phase 2 (SHARON-2 trial) planned start in Q1 2026
GO-4
BRCA-mutated cancers: Stage I-III Pancreatic, Breast, Prostate, and Ovarian
Phase 2 initiation based on positive interim Phase 2 results in BRCA+ pancreatic cancer
Ultra-high potency small molecule drug portfolio
Metastatic and non-metastatic proliferative diseases
GO-JG-1 IND enabling studies to begin 2H 2025
GO-4
Stage IV BRCA-mutated pancreatic cancer
Preclinical
IND-enabling
Phase 1
Phase 2 (Pivotal)
Submission
Next Milestone
End of phase 1 FDA meeting in Q3 2025; Preliminary Phase 1 data release in Q4 2025
GO-4
BRCA-mutated cancers: Stage I-III Pancreatic, Breast, Prostate, and Ovarian
Preclinical
IND-enabling
Phase 1
Phase 2 (Pivotal)
Submission
Next Milestone
Phase 2 initiation based on positive interim Phase 2 results in BRCA+ pancreatic cancer
Ultra-high potency small molecule drug portfolio
Metastatic and non-metastatic proliferative diseases
Preclinical
IND-enabling
Phase 1
Phase 2 (Pivotal)
Submission
Next Milestone
GO-JG-1 IND enabling studies to begin 2H 2025
SHARON: A Clinical Trial for Metastatic Cancer with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells.
We developed a pipeline of drug candidates for Stave IV solid cancers, as well as for myeloma, leukemia, and lymphoma.
We are developing a combination of melphalan, BCNU, vitamin B12b, and vitamin C for the treatment of Stage IV cancers in patients with an inherited BRCA1, BRCA2, or PALB2 mutation. Cancers currently under consideration are pancreatic and breast cancer.
Stay tuned.
